Skip to main content
. 2013 Aug 5;73(12):2094–2100. doi: 10.1136/annrheumdis-2013-203695

Figure 3.

Figure 3

Efficacy variables for week 52 certolizumab pegol (CZP) completers (N=508) and CZP intent-to-treat population (N=783). (A) Mean Disease Activity Score (DAS)28 (Erythrocyte Sedimentation Rate, ESR); (B) American College of Rheumatology Criteria (ACR)20, ACR50 and ACR70 response rates); (C) Mean Health Assessment Questionnaire – Disability Index (HAQ-DI). Efficacy variables in patients following dose reduction from CZP 400 mg Q2W to CZP 200 mg Q2W (N=436). (D) Mean DAS28 (ESR); (E) ACR20, ACR50 and ACR70 response rates. *This analysis is presented as weeks following dose-reduction visit. (‘week 0’ is defined as the final efficacy assessment visit where a patient received CZP 400 mg dose.) Total number of patients reflects imputed population. Note, sharp decline in patient numbers from week 144 following dose reduction is due to per protocol site closure in countries where CZP became commercially available.